Dual targeting of DNA damage repair pathway by BET and CDK4/6 inhibitors synergistically inhibits breast cancer

被引：0
|
作者：
Chi, S. [1 ]
Wei, F. [1 ]
Fang, Y. [1 ]
Hu, Y. [1 ,2 ]
Duan, W. [1 ,2 ]
Ding, J. [1 ,2 ]
Chen, Y. [1 ,2 ]
机构：
[1] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China
[2] Shandong Lab Yantai Drug Discovery, Bohai Rim Adv Res Inst Drug Discovery, Yantai, Peoples R China
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114732
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB202
引用
收藏
页码：S83 / S83
页数：1
相关论文
共 50 条
  • [41] Targeting CDK4/6 in patients with cancer
    Hamilton, Erika
    Infante, Jeffrey R.
    CANCER TREATMENT REVIEWS, 2016, 45 : 129 - 138
  • [42] Renoprotective effects of CDK4/6 pathway inhibitors
    Nature Reviews Nephrology, 2015, 11 (6) : 316 - 316
  • [43] Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in Prostate Cancer
    Liang, Huaiyuan
    Yang, Chunguang
    Zeng, Ruijiang
    Song, Yingqiu
    Wang, Jianxi
    Xiong, Wei
    Yan, Binyuan
    Jin, Xin
    ADVANCED SCIENCE, 2023, 10 (36)
  • [44] Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review
    Husna, Siti Muhamad Nur
    Tan, Hern-Tze Tina
    Mohamud, Rohimah
    Dyhl-Polk, Anne
    Wong, Kah Keng
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [45] Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer
    Chin, Yoon Ming
    Shibayama, Tomoko
    Chan, Hiu Ting
    Otaki, Masumi
    Hara, Fumikata
    Kobayashi, Takayuki
    Kobayashi, Kokoro
    Hosonaga, Mari
    Fukada, Ippei
    Inagaki, Lina
    Ono, Makiko
    Ito, Yoshinori
    Takahashi, Shunji
    Ohno, Shinji
    Ueno, Takayuki
    Nakamura, Yusuke
    Low, Siew-Kee
    CANCER SCIENCE, 2022, 113 (05) : 1808 - 1820
  • [46] First clinical experience with CDK4/6 inhibitors in breast cancer therapy
    Cobec, Ionut Marcel
    Moleriu, Lavinia
    Moatar, Aurica Elisabeta
    Rempen, Andreas
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (05)
  • [47] SBRT with CDK4/6 inhibitors for oligorecurrent/oligoprogressive breast cancer patients
    Ippolito, E.
    Onorati, E.
    Greco, C.
    Fiore, M.
    Silipigni, S.
    Matteucci, P.
    Cerasani, L.
    Carrafiello, S.
    Palumbo, V.
    Ramella, S.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1298 - S1298
  • [48] CDK4/6 inhibitors in HR-positive breast cancer immunotherapy
    Shen, Mimi
    Ma, Zhiyuan
    Zhu, Jiaxing
    Wen, Guorong
    Jin, Hai
    An, Jiaxing
    Tuo, Biguang
    Liu, Xuemei
    Li, Taolang
    BIOORGANIC CHEMISTRY, 2025, 154
  • [49] Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
    Barroso-Sousa, Romualdo
    Shapiro, Geoffrey I.
    Tolaney, Sara M.
    BREAST CARE, 2016, 11 (03) : 167 - 173
  • [50] The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
    Gomes, Ines
    Abreu, Catarina
    Costa, Luis
    Casimiro, Sandra
    CANCERS, 2023, 15 (19)
12345